Stock Update: Gilead Sciences Inc. (NASDAQ:GILD) – Gilead Hepatitis C Pill Leads 27 New U.S. Drug Approvals

December 31, 2013 at 12:05 PM EST

[at Bloomberg] – Gilead Sciences Inc.’s hepatitis C pill Sovaldi led 27 new U.S. drug approvals this year, a “breakthrough” therapy being chased by competitors in 2014. Read more on this. Gilead . . . → Read More: Stock Update: Gilead Sciences Inc. (NASDAQ:GILD) – Gilead Hepatitis C Pill Leads 27 New U.S. Drug Approvals Similar posts: Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1 Gilead Sciences Inc. (NASDAQ:GILD) – Gilead’s Hepatitis C Pill Works Better, FDA Report Says Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review

Gilead Sciences Inc. (NASDAQ:GILD) [at Bloomberg] – Gilead Sciences Inc.’s hepatitis C pill Sovaldi led 27 new U.S. drug approvals this year, a “breakthrough” therapy being chased by competitors in 2014.
Read more on this.

Gilead Sciences Inc. … [visit site to read more]